T
Triumvira Immunologics
At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease
About Triumvira Immunologics
Triumvira is a biotech startup that operates in the field of cancer treatment. The company's primary focus is on developing and commercializing a proprietary technology known as T cell Antigen Coupler (TAC). This technology is designed to enhance the body's natural defenses against cancer by empowering T cells, a type of white blood cell, to recognize, activate, and signal the destruction of cancer cells.
The TAC technology works by enabling T cells to target cancer cells using different antigens, which are substances that trigger an immune response. This means that the technology has broad applicability and could potentially be used to treat a wide range of both liquid and solid tumors.
Triumvira's business model revolves around the development and commercialization of this technology. The company is investing in advanced manufacturing technologies to ensure the optimum quality of its products. It is also building a robust pipeline of TAC-T cell therapies, with several programs currently in the preclinical and clinical trial stages.
Triumvira's potential clients are primarily patients with difficult-to-treat tumors. The company aims to improve the immune response of these patients and enhance their chances of survival.
In terms of revenue generation, Triumvira likely aims to make money by selling its TAC-T cell therapies to healthcare providers or directly to patients, once they have been approved for use by regulatory authorities.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2022 | $45M | $275M | Leaps by Bayer · ATEM Capital · Myeloma Investment Fund · Northpond Ventures | ↗ |
| SERIES AOther financing | Aug 2020 | $55M | $220M | Bloom Burton · Oceanpine Capital · Viva Vision Biotech · Leaps by Bayer | — |
Growth signals
Latest recorded traffic for Triumvira Immunologics is 3K monthly website visits, up 150% over the last three months. Triumvira Immunologics's team declined 4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Triumvira Immunologics in the San Francisco ecosystem
The Triumvira Immunologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Leaps by Bayer
Northpond Ventures
Bloom Burton
Oceanpine Capital
Viva Vision Biotech
C3i
B Capital
ATEM Capital
Myeloma Investment Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Triumvira Immunologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Triumvira Immunologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









